136 related articles for article (PubMed ID: 38567606)
1. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
4. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
6. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
7. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population.
Apostolakis S; Baritaki S; Krambovitis E; Spandidos DA
J Clin Virol; 2005 Dec; 34(4):310-4. PubMed ID: 16286055
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users.
Alvarez V; López-Larrea C; Coto E
Hum Genet; 1998 Apr; 102(4):483-6. PubMed ID: 9600249
[TBL] [Abstract][Full Text] [Related]
10. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.
Solloch UV; Lang K; Lange V; Böhme I; Schmidt AH; Sauter J
Hum Immunol; 2017 Nov; 78(11-12):710-717. PubMed ID: 28987960
[TBL] [Abstract][Full Text] [Related]
12. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G
Viruses; 2015 Jul; 7(8):4186-203. PubMed ID: 26225991
[TBL] [Abstract][Full Text] [Related]
13. Frequency of the CCR5 delta 32 mutant allele in HIV-1-positive patients, female sex workers, and a normal population in Taiwan.
Li C; Yan YP; Shieh B; Lee CM; Lin RY; Chen YM
J Formos Med Assoc; 1997 Dec; 96(12):979-84. PubMed ID: 9444918
[TBL] [Abstract][Full Text] [Related]
14. CCR5-Δ32 gene variant frequency in the Turkish Cypriot population.
Fahrioglu U; Ergoren MC; Mocan G
Braz J Microbiol; 2020 Dec; 51(4):1711-1717. PubMed ID: 32734471
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.
Donyavi T; Bokharaei-Salim F; Nahand JS; Garshasbi S; Esghaei M; Sadeghi M; Jamshidi S; Khanaliha K
J Med Virol; 2020 Aug; 92(8):1158-1164. PubMed ID: 31854469
[TBL] [Abstract][Full Text] [Related]
17. CC chemokine receptor 5 Δ32 polymorphism: association analysis and allele distribution among cutaneous leishmaniasis patients from Pakistan.
Sophie M; Hameed A; Muneer A; Samdani AJ; Saleem S; Azhar A
J Cutan Pathol; 2016 Jul; 43(7):564-70. PubMed ID: 26970327
[TBL] [Abstract][Full Text] [Related]
18. Identification of the CCR5-Delta32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations.
Jlizi A; Edouard J; Fadhlaoui-Zid K; Frigi S; Debré P; Slim A; Theodorou I; El Gaaied AB; Carpentier W
Hum Immunol; 2007 Dec; 68(12):993-1000. PubMed ID: 18191728
[TBL] [Abstract][Full Text] [Related]
19. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
[TBL] [Abstract][Full Text] [Related]
20. Increased Efficiency for Biallelic Mutations of the
Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
